GB202003277D0 - Therapeutic agents - Google Patents

Therapeutic agents

Info

Publication number
GB202003277D0
GB202003277D0 GBGB2003277.7A GB202003277A GB202003277D0 GB 202003277 D0 GB202003277 D0 GB 202003277D0 GB 202003277 A GB202003277 A GB 202003277A GB 202003277 D0 GB202003277 D0 GB 202003277D0
Authority
GB
United Kingdom
Prior art keywords
therapeutic agents
therapeutic
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2003277.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kings College London
Original Assignee
Kings College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kings College London filed Critical Kings College London
Priority to GBGB2003277.7A priority Critical patent/GB202003277D0/en
Publication of GB202003277D0 publication Critical patent/GB202003277D0/en
Priority to PCT/EP2021/055566 priority patent/WO2021176042A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF] (urogastrone)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
GBGB2003277.7A 2020-03-06 2020-03-06 Therapeutic agents Ceased GB202003277D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2003277.7A GB202003277D0 (en) 2020-03-06 2020-03-06 Therapeutic agents
PCT/EP2021/055566 WO2021176042A1 (en) 2020-03-06 2021-03-05 Therapeutic agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2003277.7A GB202003277D0 (en) 2020-03-06 2020-03-06 Therapeutic agents

Publications (1)

Publication Number Publication Date
GB202003277D0 true GB202003277D0 (en) 2020-04-22

Family

ID=70278386

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2003277.7A Ceased GB202003277D0 (en) 2020-03-06 2020-03-06 Therapeutic agents

Country Status (2)

Country Link
GB (1) GB202003277D0 (en)
WO (1) WO2021176042A1 (en)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
ES2392073T3 (en) 2001-11-08 2012-12-04 Abbott Biotherapeutics Corp. Stable liquid pharmaceutical formulation of IGG antibodies
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
CA2634547C (en) 2005-12-20 2016-10-11 Bristol-Myers Squibb Company Stable ctla4 formulation for subcutaneous administration
WO2008005983A2 (en) * 2006-07-06 2008-01-10 Molecular Logix, Inc. Pan-her antagonists and methods of use
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
EP3066118B1 (en) * 2013-11-06 2020-01-08 The U.S.A. as represented by the Secretary, Department of Health and Human Services Alk antibodies, conjugates, and chimeric antigen receptors, and their use
GB201513540D0 (en) 2015-07-31 2015-09-16 King S College London Therapeutic agents
CN106967173A (en) * 2016-01-13 2017-07-21 上海嘉和生物科技有限公司 The chimeric memebrane protein of one kind restructuring and its preparation and application
EP3336107A1 (en) * 2016-12-15 2018-06-20 Miltenyi Biotec GmbH Immune cells expressing an antigen binding receptor and a chimeric costimulatory receptor
US20210207174A1 (en) * 2018-05-25 2021-07-08 The Regents Of The University Of California Genetic engineering of endogenous proteins

Also Published As

Publication number Publication date
WO2021176042A1 (en) 2021-09-10

Similar Documents

Publication Publication Date Title
GB201909190D0 (en) Therapeutic agents
GB201909194D0 (en) Therapeutic agents
GB201909191D0 (en) Therapeutic agents
GB201902277D0 (en) Therapeutic agents
GB201906804D0 (en) Therapeutic agents
GB202010606D0 (en) Therapeutic agents
GB202115770D0 (en) Therapeutic agents
GB202115366D0 (en) therapeutic agents
GB202114792D0 (en) Therapeutic agents
GB202114507D0 (en) Therapeutic agents
GB202114429D0 (en) Therapeutic agents
GB202112860D0 (en) Therapeutic agents
GB202111639D0 (en) Therapeutic agents
GB202110567D0 (en) Therapeutic agents
GB202110120D0 (en) Therapeutic agents
GB202109583D0 (en) Therapeutic agents
GB202109520D0 (en) Therapeutic agents
GB202108945D0 (en) Therapeutic agents
GB202019702D0 (en) Therapeutic agents
GB202017640D0 (en) Therapeutic agents
GB202017641D0 (en) Therapeutic agents
GB202012731D0 (en) Therapeutic agents
GB202012501D0 (en) Therapeutic agents
GB202012481D0 (en) Therapeutic agents
GB202010607D0 (en) Therapeutic agents

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)